The verdict
Our read at a glance.
Whether apelin's cardiovascular and metabolic biology, tested in small human studies, supports the broader metabolic and performance claims made for apelin and its analogs.
- The signal
- Small human studies have tested apelin and analogs, mainly in heart failure and pulmonary blood pressure, showing short-term effects on heart function and blood vessels. The evidence is early and limited, and there is no approval for any use.
- The unknown
- Whether apelin-based drugs can produce lasting benefit in heart or metabolic conditions, and whether any of the metabolic or performance claims have a basis in people.
- Our read
- A real cardiovascular peptide with early, small human evidence, not a proven treatment. Apelin's heart and vessel effects are genuine in short studies, but it remains investigational, and the metabolic and performance claims are not established.
The mechanism
How it works.
Apelin is a short natural peptide and the main ligand for the APJ receptor, a G-protein-coupled receptor found on heart muscle and the cells lining blood vessels. When it binds APJ on heart cells it increases the force of contraction, and when it binds APJ on vessels it triggers nitric-oxide release that relaxes them and lowers vascular resistance. Those acute effects are what small human heart-failure and pulmonary-hypertension studies have measured, but native apelin is cleared from the blood very quickly, so the work has moved toward longer-acting analogs.
Safety & regulatory boundary
The consequential part.
Apelin and its analogs are not approved drugs, and the human evidence is early and small. Research-labeled or compounded apelin is not an approved product. Its cardiovascular biology does not establish metabolic or performance benefits, and short-term study effects are not the same as proven treatment.
What's next
What we're watching.
Larger trials of apelin analogs in heart failure and pulmonary conditions, and any metabolic research.
Context
Why this is discussed.
Apelin acts on the heart and metabolism, which connects serious heart-failure research to the metabolic and performance claims made for it.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NOT_YET_RECRUITING · 2026-05-17
ClinicalTrials.gov · NA · COMPLETED · 2010-10-19
ClinicalTrials.gov · NA · COMPLETED · 2025-05-27
ClinicalTrials.gov · NA · COMPLETED · 2016-02
ClinicalTrials.gov · COMPLETED · 2023-08-24
ClinicalTrials.gov · NA · RECRUITING · 2026-02-03
ClinicalTrials.gov · COMPLETED · 2019-12-15
ClinicalTrials.gov · NA · COMPLETED · 2025-01-20
Indexed literature (PubMed)12
Pan X et al. · Nature · 2024
Chapman FA et al. · Cardiovasc Res · 2023
Song K et al. · Nat Commun · 2022
Fève B et al. · Ann Endocrinol (Paris) · 2016
Yang Y et al. · Clin Chim Acta · 2016
Tang L et al. · Circ Res · 2024
Gao S et al. · Biomed Pharmacother · 2023
Yu XH et al. · Clin Chim Acta · 2014
Li C et al. · Front Endocrinol (Lausanne) · 2022
Sekerci R et al. · Acta Histochem · 2018
Wang X et al. · Int Immunopharmacol · 2022
Chandrasekaran B et al. · Eur J Heart Fail · 2008
Keep reading